Hannah L Turner

List of Publications by Year
in descending order

49 papers	5,609 citations	136885 32 h-index	223716 46 g-index
60 all docs	60 docs citations	60 times ranked	8266 citing authors

#	Article	IF	Citations
1	Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination. Cell Reports, 2021, 34, 108682.	2.9	31
2	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. PLoS Pathogens, 2021, 17, e1009282.	2.1	42
3	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
4	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	1.5	6
5	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell, 2021, 184, 1188-1200.e19.	13.5	154
6	Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. Science Advances, 2021, 7, .	4.7	37
7	Human antibody recognition of H7N9 influenza virus HA following natural infection. JCI Insight, 2021, 6, .	2.3	1
8	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. Journal of Clinical Investigation, 2021, 131, .	3.9	20
9	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	6.0	290
10	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells. Protein Science, 2020, 29, 1975-1982.	3.1	6
11	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathogens, 2020, 16, e1008665.	2.1	52
12	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. Science Advances, 2020, 6, eaba0512.	4.7	18
13	Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell Reports, 2020, 30, 3755-3765.e7.	2.9	81
14	Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 2020, 26, 430-440.	15.2	172
15	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity, 2020, 52, 388-403.e12.	6.6	71
16	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. Journal of Virology, 2020, 94, .	1.5	57
17	Antiâ€"influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface. Journal of Clinical Investigation, 2020, 130, 4734-4739.	3.9	13
18	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathogens, 2020, 16, e1009089.	2.1	55

#	Article	IF	Citations
19	Title is missing!. , 2020, 16, e1008665.		0
20	Title is missing!. , 2020, 16, e1008665.		0
21	Title is missing!. , 2020, 16, e1008665.		0
22	Title is missing!. , 2020, 16, e1008665.		0
23	Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15194-15199.	3.3	65
24	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Reports, 2019, 28, 3395-3405.e6.	2.9	63
25	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. PLoS Biology, 2019, 17, e3000139.	2.6	37
26	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell, 2019, 177, 1136-1152.e18.	13.5	177
27	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Immunity, 2019, 51, 915-929.e7.	6.6	111
28	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host and Microbe, 2019, 26, 729-738.e4.	5.1	51
29	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. Cell Host and Microbe, 2019, 26, 715-728.e8.	5.1	49
30	Fluorescent Trimeric Hemagglutinins Reveal Multivalent Receptor Binding Properties. Journal of Molecular Biology, 2019, 431, 842-856.	2.0	36
31	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. Nature Communications, 2018, 9, 877.	5.8	65
32	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell Reports, 2018, 23, 90-99.	2.9	80
33	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific Reports, 2018, 8, 15701.	1.6	408
34	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science, 2018, 362, 598-602.	6.0	170
35	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S612-S626.	1.9	146
36	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity, 2018, 49, 288-300.e8.	6.6	175

#	Article	IF	Citations
37	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity, 2018, 49, 363-374.e10.	6.6	61
38	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
39	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017, 19, 413-424.	2.9	66
40	In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Nature Communications, 2017, 8, 15371.	5.8	55
41	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	13.5	145
42	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	13.5	103
43	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. Journal of Virology, 2017, 91, .	1.5	15
44	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7348-E7357.	3.3	944
45	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	13.7	623
46	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology, 2016, 1, 16128.	5.9	92
47	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	2.9	80
48	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	13.5	160
49	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science, 2016, 351, 1078-1083.	6.0	194